Ovarian cancer with BRCA1/2 mutations shows higher immune infiltrates, including CD3+ and CD8+ T-cells, high PD-1 expression, and an association with BRCA1 mutation or loss of function, suggesting possible suitability for immune checkpoint blockade therapy [44,46]. This evidence concerns the gene BRCA1 and ovarian cancer.